Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Zhongnan Hospital is the lead sponsor of 31 current clinical trials in our China register. 20 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are 68Ga-FAPI, 68Ga-pentixafor and Anlotinib. The most-studied condition is PET/CT.

ClinicalTrials.gov trials by status

Recruiting2065%
Not yet open619%
Active, closed413%
By invitation13%

Trials by phase

Observational1135%
Not applicable1032%
Phase 2413%
Phase EARLY_PHASE126%
Phase 113%
Phase 313%
Phase 1/213%
Phase 2/313%

Clinical trials sponsored by Zhongnan Hospital

31 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics for Patients With Advanced Malignant Solid Tumors NCT07121036 · ClinicalTrials.gov ↗ · Vitamin C	Phase 1	Recruiting	2025-03	China
Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection NCT06667063 · ClinicalTrials.gov ↗ · COVID-19, Influenza	Observational	Recruiting	2024-09	China
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC NCT07291401 · ClinicalTrials.gov ↗ · Rectal Cancer Patients	Phase 2	Recruiting	2025-11	China
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy NCT06858709 · ClinicalTrials.gov ↗ · Chemotherapy-induced Peripheral Neuropathy (CIPN), Cancer	Not applicable	Recruiting	2025-03	China
Integrin αvβ6-targeted PET in Malignant Tumors NCT05835570 · ClinicalTrials.gov ↗ · Malignant Neoplasm, PET/CT, Non-Small Cell Lung Cancer	Observational	Recruiting	2023-01	China
The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis NCT07539675 · ClinicalTrials.gov ↗ · Primary Angle-Closure Glaucoma	Observational	Recruiting	2025-10	China
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) NCT06345365 · ClinicalTrials.gov ↗ · Acute Myeloid Leukaemia	Phase 3	Recruiting	2024-01	China
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer NCT05817214 · ClinicalTrials.gov ↗ · Cervical Cancer Drugs: Anlotinib, Cadonilimab	Phase 2	Recruiting	2023-02	China
The Effect of Eyeliner on Tear Composition, Tear Secretion and Tear Film Stability. NCT05632887 · ClinicalTrials.gov ↗ · Dry Eye	Observational	Recruiting	2022-11	China
The Value of Bowel Sounds in Evaluating Postoperative Intestinal Function Recovery in Colorectal Cancer Patients NCT07705139 · ClinicalTrials.gov ↗ · Bowel Sounds, Colorectal Cancer, Intestinal Obstruction	Observational	Recruiting	2026-02	China
Effects of Acupoint Massage Around Eyes on Ocular Biological Indexes NCT06293196 · ClinicalTrials.gov ↗ · Investigating the Effects of Periocular Acupressure on Ocular Biological Indicators	Not applicable	Recruiting	2023-09	China
Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood NCT06082765 · ClinicalTrials.gov ↗ · Cervical Cancer	Observational	Recruiting	2021-09	China
Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation NCT07453966 · ClinicalTrials.gov ↗ · Pneumonia	Not applicable	Recruiting	2026-03	China
CXCR4-targeted PET/CT Imaging in Hematological Malignancies NCT05255926 · ClinicalTrials.gov ↗ · CXCR4, PET/CT, Hematological Malignancy Drug: 68Ga-pentixafor	Not applicable	Recruiting	2022-03	China
Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients NCT06757153 · ClinicalTrials.gov ↗ · Glioblastoma (GBM) Drug: NRG-103	Phase EARLY_PHASE1	Recruiting	2024-12	China
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education NCT07305337 · ClinicalTrials.gov ↗ · Leukaemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Lymphoma	Not applicable	Recruiting	2025-06	China
A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability NCT07460258 · ClinicalTrials.gov ↗ · Accuracy in Understanding the Core Content of English Medical Literature	Observational	Recruiting	2026-01	China
68Ga-FAPI PET/CT in Malignant Tumors NCT05034146 · ClinicalTrials.gov ↗ · Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm Drug: 68Ga-FAPI	Not applicable	Recruiting	2021-02	China
Comparative Study of TIS Efficacy Across Different Targets NCT07745673 · ClinicalTrials.gov ↗ · PARKINSON DIS	Not applicable	Recruiting	2026-06	China
Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy NCT07713056 · ClinicalTrials.gov ↗ · Pigmentary Glaucoma	Observational	Recruiting	2026-04	China
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer NCT07363330 · ClinicalTrials.gov ↗ · Cervical Cancer, Recurrent, Metastatic Drugs: Toripalimab, Utidelone	Phase 2	Not yet open	2026-02	China
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors NCT07420036 · ClinicalTrials.gov ↗ · Neoplasms	Phase EARLY_PHASE1	Not yet open	2026-03	China
FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. NCT07515963 · ClinicalTrials.gov ↗ · Colo-rectal Cancer	Phase 2	Not yet open	2026-06	China
Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors NCT07385950 · ClinicalTrials.gov ↗ · PET / CT, Solid Tumors, Adult	Observational	Not yet open	2026-01	China
The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models NCT06768853 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Not applicable	Not yet open	2025-01	China
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy NCT06916442 · ClinicalTrials.gov ↗ · PET/CT, Solid Tumors, Adult, Solid Tumors, Advanced Solid Tumors	Observational	Not yet open	2025-04	China
Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study NCT06890871 · ClinicalTrials.gov ↗ · Breast Cancer, Metastatic Breast Cancer	Phase 1/2	By invitation	2024-08	China
Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance NCT06660784 · ClinicalTrials.gov ↗ · Tracheal Intubation, Extracorporeal Membrane Oxygenation, Nitric Oxide Drug: Nitric Oxide	Observational	Active, closed	2024-01	China
A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection NCT06662643 · ClinicalTrials.gov ↗ · Rectal Cancer, Rectal Carcinoma	Not applicable	Active, closed	2024-05	China
Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma NCT07201415 · ClinicalTrials.gov ↗ · Neovascular Glaucoma	Not applicable	Active, closed	2025-01	China
A Multicenter, Randomized, Double-blind, Positive-control, Non-inferiority Clinical Trial on the Effectiveness and Safety of HCA-N Solution for the Preservation of Kidney Grafts During Kidney Transplantation NCT07825025 · ClinicalTrials.gov ↗ · Kidney Transplant	Phase 2/3	Active, closed	2025-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Zhongnan Hospital trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

68Ga-FAPI1 68Ga-pentixafor1 Anlotinib1 Cadonilimab1 NRG-1031 Nitric Oxide1 Toripalimab1 Utidelone1

Conditions in Zhongnan Hospital trials

49 conditions

PET/CT4 Cervical Cancer3 Malignant Neoplasm2Vitamin C1COVID-191 Influenza1 Rectal Cancer Patients1Chemotherapy-induced Peripheral Neuropathy (CIPN)1Cancer1Recurrent1Metastatic1Non-Small Cell Lung Cancer1 Breast Cancer, Metastatic1Primary Angle-Closure Glaucoma1Tracheal Intubation1Extracorporeal Membrane Oxygenation1Nitric Oxide1Ventilator-induced Diaphragmatic Dysfunction1Acute Myeloid Leukaemia1Neoplasms1Dry Eye1Bowel Sounds1Colorectal Cancer1Intestinal Obstruction1

By trial register

Register	Trials	Recruiting
Clinical trials in China	31	20

A trial with sites in more than one country appears in each of those registers.

Other sponsors in PET/CT

Sponsor	Trials
The First Affiliated Hospital of Xiamen University	5

Sponsors with the most current trials registered for this condition.

Questions about Zhongnan Hospital trials

How many clinical trials does Zhongnan Hospital sponsor?

Zhongnan Hospital is the lead sponsor of 31 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Zhongnan Hospital trials recruiting?

Yes. 20 of its 31 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Zhongnan Hospital testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are 68Ga-FAPI (1), 68Ga-pentixafor (1), Anlotinib (1), Cadonilimab (1) and NRG-103 (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Zhongnan Hospital clinical trials